GT Biopharma gets Nasdaq extension to regain $1 minimum bid price compliance

• GT Biopharma received a Nasdaq notice granting an extra 180-day window, through Nov. 16, 2026, to regain compliance with the $1 minimum bid price rule.
• The extension follows an initial compliance period that ended May 19, 2026, triggered when the stock traded below $1 for 30 consecutive business days.
• Nasdaq will clear the deficiency if the closing bid price reaches at least $1 for 10 consecutive business days, subject to staff discretion.
• Failure to regain compliance by the deadline raises the risk of delisting from the Nasdaq Capital Market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GT Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-024913), on May 22, 2026, and is solely responsible for the information contained therein.